Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Garber

Showing results (41-50 of 194) with videos related to

Pageof 20
Sort By:
Nature Biotechnology|April 9, 2005
New apoptosis drugs face critical testKen Garber
Journal of the National Cancer Institute|June 2, 2005
IGF-1: old growth factor shines as new drug targetKen Garber
Journal of the National Cancer Institute|March 7, 2002
Battle over generic taxol concludes, but controversy continuesKen Garber
Journal of the National Cancer Institute|December 22, 2005
Targeting mitochondria emerges as therapeutic strategyKen Garber
Nature Biotechnology|August 6, 2014
Between disease and a dishKen Garber
Nature Biotechnology|May 10, 2013
Principia BiopharmaKen Garber
Nature|December 21, 2012
Genetics: Deep explorationKen Garber
Science (New York, N.Y.)|December 11, 2012
Neuroscience. All eyes on RNAKen Garber
Nature Reviews. Drug Discovery|October 2, 2013
PARP inhibitors bounce backKen Garber
Nature Biotechnology|December 8, 2016
Alnylam terminates revusiran program, stock plungesKen Garber
Pageof 20

Showing results (41-50 of 194) with videos related to

Sort By:
Pageof 20
Nature Biotechnology|April 9, 2005
New apoptosis drugs face critical testKen Garber
Journal of the National Cancer Institute|June 2, 2005
IGF-1: old growth factor shines as new drug targetKen Garber
Journal of the National Cancer Institute|March 7, 2002
Battle over generic taxol concludes, but controversy continuesKen Garber
Journal of the National Cancer Institute|December 22, 2005
Targeting mitochondria emerges as therapeutic strategyKen Garber
Nature Biotechnology|August 6, 2014
Between disease and a dishKen Garber
Nature Biotechnology|May 10, 2013
Principia BiopharmaKen Garber
Nature|December 21, 2012
Genetics: Deep explorationKen Garber
Science (New York, N.Y.)|December 11, 2012
Neuroscience. All eyes on RNAKen Garber
Nature Reviews. Drug Discovery|October 2, 2013
PARP inhibitors bounce backKen Garber
Nature Biotechnology|December 8, 2016
Alnylam terminates revusiran program, stock plungesKen Garber
Pageof 20